visibility Thank update, today's you, and good and Christian, afternoon, everyone. On prioritization. clinical the theme will be
the resources that first slide our slide prioritizing outlines of STAR-T execution. of to my we include our The ensure is horse summary that U.S. market to presentation are will speedy with and the now a as all highlights lead
to visibility summer. better month. on very we we showing an hit STAR-D approval of update patients our enrollment the preserve STAR-T FDA pause project to short-term. to in #X expand that with STAR-T, STAR-T to to milestone rates guidance Meanwhile, uptick greater trial country STAR-T now next that later and are XX projecting enrolled will this into The with with high will with a recently updated allow Canada, received the use. And temporarily ticagrelor complete and now the focus rate activities of enrollment cash We
STAR-D improves, will comes crosses STAR-T finish situation whichever first. or or as our line resume the financial
the antithrombotic real and the world data proposition, dominant more international share highlighting and registry will Our a economic value clinical is on later. STAR on in penetration that of increasing some removal fast, topic enrolling based I
of Society critical And with And European excellent this stream -- our the care Medicine outcomes respiratory with main XX we at The severe our publications in we most presented turned enhanced over Intensive combining have registry and of positive the lung presentations continuing. enhanced surgery CytoSorb patients right pioneering and of ECMO rest results strategy data Care failure, in plus ARDS. strategy CytoSorb recently, with the otherwise year. constant lung of with CTC already cardiac original now, is use
please. slide, Next
the for Now study STAR-T specifically.
for trigger complete the for by We after and this meeting to DSMB very enrolling. approximately the months target the scheduled anticipate numbers first and enrollment day place sites of take follow-up and some the increasing that for allow reaching encouraged actively which of later anticipate we later reach pace XX to will cleaning. the data STAR-T we to two XX are month, that are patients enrollment We
be will XX a issuing hit We when tuned. press the stay please release so we patient mark,
be the enrollment We to received FDA based the an to Canada, expand additional approval that this we will on believe to following. tailwind study and
in as use is ACS ticagrelor First, Canada it for preferred protocol. the ubiquitous, is treatment agent
patients participate high anticipate to of we So the in study. eligible numbers
track centers CV as Canadian in and excellent finishing enrollers volume trials. an frequently in have top Second, are high in very executing these trials record surgery sites
third, actively investigator investigator with an included are will an as Whitlock Richard delighted for STAR-T. internationally time can visibility network of Canada below. All milestone in principal Canada. a Health STAR-T now, to including to increased we in in established operational submission And completed that With high-performing the to our is shown Dr. steps line the sign Canada. be Whitlock as renowned Dr. to have Canada completion all project stopped we stable progressing, are
that will summer. in the and trial patient we XXX its and already next number the milestone first As DSMB the of later the meeting hitting second continue month, mentioned, we patients the trigger take that that spring to XX full we the enrollment, interim next anticipate would anticipate reach project anticipate of to analysis enrollment sometime year. we in this place Should
and our The well full can execution path execution. accelerate Canada progressing please. study is speed approval it further also trial and up development momentum progress apparent Canadian that has to this to and expansion dynamics, some to but with may focus tool. with our potential increasingly that and speed attention for based to-date and for all of we further The Next positive we downstream have And resourcing the positive the important our study on and resources, is further market fastest STAR-T need our its the is slide, research is market. a fuel we DrugSorbATR. believe enrollment, significantly to either U.S. implications
trial In these that us market important capitalize accelerate, addition opportunity. market to evolving desirable makes highly are to reasons specific to on to growing speed for dynamics there the
ticagrelor broader high go barrier with will in remove as This ticagrelor would grow Otherwise likely adoption. the stated, availability. is First, currently to expected a is that generic to serving generic XXXX. key cost use
cardiologists a patients cardiovascular XX better high-risk aspirin potentially a months this is in Simply than ticagrelor a periods is increasingly by implication drug of means therapy. becoming for treated actually to use considered prescribed The as more Second, paradigm this ticagrelor approach longer patients. shift from for time. monotherapy that being could shift for protection put, treatment lifelong of
advantage to market. potential mover in the Also, first the
patients, Although, is potentially reversal we on and broad you believe the for application likely events reversal. some always real a and the the world to ticagrelor the drug focusing technology strategy, how adoption a preferred we're finally, bleeding told that preventing these currently this recently, will antithrombotic And enthusiastic likely development drug with forward playing have in seen in is removal. is complicate seeing or removal competitive that for path
have STAR today, in enrolled conferences and is registry, Our readout we presentation as to submission ahead targeting schedule, next the international patients international year. data XXX initial we and beginning the already already registry are of of
are a this on on STAR-T a line first. our or we emphasize studies. It crosses our accelerating remain With that sequential we will activities execution speedy finish resources the slide. Next position activities are focus that resume to business financial whichever parallel is STAR-T from a STAR-D when and of will a and STAR-D, will STAR-T the no two execution. shift issue we We to STAR to is important solely and focus of Accordingly, our fully once all pausing increased or committed to clinical very there improves, decision. safety comes completion,
to accelerating our XX% have than in date fact, since almost sites, remain in take We more introduce to advantage this plan action have necessary on that pause impact resumed ensure also now will that fine-tune enrollment fixes STAR-T enrollment. on learnings minimal and the we'll study the to all based focused them, active that open enrollment of once anticipate trial. study of are on will to We in this and speedy
in the execution will with we Finally, sequential million. at trials, STAR observe estimated approximately XXXX the near-term of significant $X savings cost
U.S. now will catalyst the to greater next major detail of believe growth We'll Shifting couple our Next releases focus discussed the in conferences business. the in FDA slide. in the review. also on spend from we at highlights that minutes of slides you of were trials. online data new next reviewing exciting crucial are recently data recent two be our the presented that press The available for also driving international
presentations of the conference overview Let's of European the outside U.S. Surgery with This the start in is Cardio-Thoracic October the Association early Milano, in cardiac a brief at largest Italy. in for surgery
So a it's exciting major data being presented. form of very
important First, benefits a high-risk is types that rates to endocarditis. CytoSorb of using endocarditis endocarditis. this staph serious Germany of with than most everyone the and higher is cardiac demonstrated endocarditis multicenter significantly type surgery staph of It for the remind other patients in -- aureus the associated mortality is type from undergoing aureus report
for related these significantly also postoperative study vasopressor support by reduced mortality. hemodynamics in reducing but the to CytoSorb sepsis The main with patients this need both observations overall improved that maintain it course from and
In a the so mortality patients need reduction to will be fact, to death. in only profound five that prevent was treated
also but the were both economic on this on presented application. that to antithrombotic the benefits Moving removal also for clinical,
days to significant impressive less to and EURX,XXX surgery that fewer inclusive also the and transfusions, in per operative primarily fewer in spend investigators cost reductions of repeat benefits of by ICU. for bleeding, dedicated the addition elimination of risk were executed tested savings showed the the including of These and economic driven case, cost the a bleeding, drainage control a In analysis device. reductions total cost in times
of and study, the In frequent show heart turn shorter mechanical was X.X course the able lower transplantation to once first kidney and postoperative postoperative ICU. of the spent clinical trial injury was into vasoplegia Hungary. presentation Finally, of smoother CytoSorb that associated on investigators use with ventilation, data that that in a less very the overall from days in ever acute again of exciting were occurrence times translated fewer in randomized rates
therapy proposition heart With the a value surgeons conference to world, interactions these robust our during of that around a that type offers data, the we was sentiment echoed with participants. believe our
Next slide, please.
already Intensive heard European exciting I'd in I'd our you well press You've release was CTC Care the of few to the about today. that the refer as results that at Society from just But highlights a recent data Medicine registry again, to like presented share details. a to days you ago. with discusses like some Once
academic registry in set ill was As CTC respiratory under use emergency with a of treatment the reminder, COVID-XX authorization critically The patients failure. of were the States for the data the comprises final United type treated executed registry centers. five ECMO membrane the extracorporeal at that of XXX oxygenation, who large of known sickest of otherwise COVID-XX required support with as patients U.S. life
getting to lungs the blood at ARDS, with employed in can believe The rationale and key vessel reverse and a but cause a lung cytokines and avoid also removes capillary therefore, CytoSorb The this goal, which to toxins of rest this a enhanced those with use combined of these feature survive. allowing a to strategy and we ECMO. that other allow heal, lung and strategy rest to these is injury, CytoSorb clinical strategy to the that patients is for and leak use lungs teams of key helps while centers ventilator-induced to patients rest, ultimately, them is ECMO ARDS. designations mechanical ECMO lung of injury off actively support inflammatory mechanical The rest syndrome, enhanced
reported survival outcomes U.S. International compare as before high CTC from a ECMO to present. as registry as in and strategy. started with organ the favorably that specifically reported survival that irreversible patients registry be registry. XX% for data registry of was with damage and very excellent survival the XX% by this CTC possible benefit most early additional The An CytoSorb rates to important observation the is gain the should with combined
We are very reasons. data for the multiple on bullish CTC
CytoSorb this this the information only multicenter other First, trumping of the data and is all with largest with plus ECMO, application.
the registry that we lung And observed Second, data in and excellent enhanced relevant these as outcomes serve of population. broader believe ARDS our strategy. to validation rest the ECMO third, are treatment
our detail in much is pathophysiologic Chris, mechanisms benefit VP Development that discuss as for the greater the presentation, technology organ part the will at of the of it exact ECOS believe of Business next Finally, our preservation. in same we support play
slide. Next
to So summarize.
is project slide, increased our Next #X new next hit STAR-T addition spring please. the visibility, coming we have and of with respectively. With tailwind Canada. and a in and month milestone we X accelerating, milestone X to summer, this and
capitalize PB our favorable look to top execution we'll priority, study dynamics, also in STAR-T is where on both related but market-related dynamic.
XXXX on estimated We are STAR-T, significant million. $X to contribute savings in our be pausing also cost focus to increase STAR-D, but
of ahead is of real-world in of registry schedule, care increased standard antithrombotic the STAR Our of demonstrating adoption removal practice.
I and increasing area our all teams. regards of multiple business from released. our reviewed adoption just therapy with that supporting on efforts, anticipate And heels the medical In different recently publications, presentations remains our you medical priority a therapeutic the to data top our of of positive we
like would to turn the over I Chris? that, call with to And Chris.
